Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (10954)	11/10/1997 5:27:00 PM
From: Andrew H	Read Replies (2) \| Respond to of 32384

Thanks, Henry. A decent day for LGND, all things considered. The Henderson game sounds great!!! We will all be rooting for the girls. See that Nicole gets some sleep.

To: Henry Niman who wrote (10954)	11/10/1997 8:25:00 PM
From: Andrew H	Read Replies (1) \| Respond to of 32384

Henry, if you are busy with FC, there is no hurry to answer this. I am reprinting part of a post from Rocketman on the VD thread in regard to the new FDA law passed by Congress and expected to be signed by Clinton. Will be nice to see a copy of the bill, but from the statement below it looks very favorable for the whole industry and for patients. >>Hey V1, caught the FDA Modernization Act of 1997 the Senate passed to Clinton yesterday, and it's expected he'll sign it. BioCentury covered it, haven't seen it mentioned elsewhere yet. <<<<<<<<<<< The legislation would codify the ability of a single well-controlled clinical study to demonstrate efficacy, as well as impose requirements on the designation of fast-track status on products that meet statuatory criteria.<< What I am curious about here is how this will affect LGND drugs which have already completed one successful P3. I am thinking particularly of Targretin. Hopefully they will only have to do one trial in regard to psoriasis and APL. I am also wondering if the 11/111 trial for lung cancer might come under this heading. In any case it would be great to hear your comments in regard to how this might affect LGND drugs currently in or entering advanced trials. Thanks.